CUE.US Cue Biopharma

Healthcare Biotechnology USA Stocks
16.12 USD
Close of Nov 13, 2026
4.97 45.50
Market cap
USD 117M
P/E
-
P/B
55.01x
ROE
-13,700.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is CUE.US undervalued?

Graham number

The Graham number of Cue Biopharma cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cue Biopharma fundamental analysis

No fundamental analysis for Cue Biopharma yet.

Cue Biopharma stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cue Biopharma

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-…

Full company profile